Astrazeneca Plc $AZN Shares Sold by Gibbs Wealth Management

Gibbs Wealth Management lessened its stake in Astrazeneca Plc (NYSE:AZN) by 28.8% during the 1st quarter, HoldingsChannel reports. The firm owned 8,293 shares of the company’s stock after selling 3,351 shares during the quarter. Gibbs Wealth Management’s holdings in Astrazeneca were worth $1,636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its holdings in Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after purchasing an additional 2,789 shares during the period. AQR Capital Management LLC raised its stake in shares of Astrazeneca by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after buying an additional 11,690 shares during the period. Amundi lifted its position in shares of Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after buying an additional 3,618 shares in the last quarter. Jump Financial LLC lifted its position in shares of Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after buying an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in Astrazeneca by 1.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.8%

Shares of Astrazeneca stock opened at $168.41 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock’s 50 day simple moving average is $180.80 and its 200-day simple moving average is $188.05. The stock has a market cap of $261.19 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.38 and a beta of 0.24. Astrazeneca Plc has a 1-year low of $142.98 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Analysts predict that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.